1.0 Abstract
AbbVie to present new and updated data from 22 abstracts
1.0 Abstract
AbbVie Ends Tau Antibody Study - CurePSP
PDF) Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
Participation in an innovative patient support program reduces prescri | PPA
NCT03419403
Frontiers | Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy | Neurology
Summary of Clinical Trial Results
PDF) Higher Medication Adherence and Lower Opioid Use Among Individuals with Autoimmune Disease Enrolled in an Adalimumab Patient Support Program in the United States
1.0 Abstract
AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
Summary of Clinical Trial Results
AbbVie takes anti-tau drug into phase II for Alzheimer's - PMLiVE
1.0 Abstract
Clinical Study Protocol M15-563 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Incorporating Administra
Progressive Supranuclear Palsy Treatment Market Estimated to Reach A Valuation Of US$ 20.68 Million By 2027 – with AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc.,
PDF) Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study
1. Abstract
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES • The Journal of Prevention of Alzheimer's Disease
AbbVie to present new and updated data from 22 abstracts
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares - ACR Meeting Abstracts
Sony officially announces PSP Go
Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study - Clinical Therapeutics
